NousCom

NousCom is a biotechnology company focused on tumor immunotherapy, primarily concentrating on the development of next-generation cancer treatments: neoantigen gene vaccines and specific oncolytic immunotherapies. NousCom has developed a novel viral vector technology platform—Endovax—that can design specialized recombinant viral vector systems to enhance the activation of anti-cancer immune responses. The most significant highlight of NousCom’s unique approach to tumor immunology is its ability to provide off-the-shelf ready-made cancer vaccines, which may overcome the current bottlenecks of complex production processes, high costs, and long cycles associated with approved engineered immune cell therapies on the market.